ISAB Stock Overview
Inhalation Sciences Sweden AB (publ) develops and sells labtech equipment for inhalation research. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Inhalation Sciences Sweden AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 4.34 |
| 52 Week High | SEK 4.99 |
| 52 Week Low | SEK 2.43 |
| Beta | 0.52 |
| 1 Month Change | 0% |
| 3 Month Change | 6.90% |
| 1 Year Change | 24.36% |
| 3 Year Change | -56.07% |
| 5 Year Change | -43.86% |
| Change since IPO | -53.08% |
Recent News & Updates
Shareholder Returns
| ISAB | SE Life Sciences | SE Market | |
|---|---|---|---|
| 7D | 0% | -1.6% | -2.7% |
| 1Y | 24.4% | 16.5% | 4.6% |
Return vs Industry: ISAB exceeded the Swedish Life Sciences industry which returned -1.4% over the past year.
Return vs Market: ISAB exceeded the Swedish Market which returned 8.6% over the past year.
Price Volatility
| ISAB volatility | |
|---|---|
| ISAB Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 7.6% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.3% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: ISAB has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ISAB's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 8 | Manoush Masarrat | www.inhalation.se |
Inhalation Sciences Sweden AB (publ) develops and sells labtech equipment for inhalation research. The company’s products portfolio includes PreciseInhale, a laboratory system that allows scientists to measure how inhaled particles act in lungs and affect the health; DissolvIt, which enables in vitro simulation of dissolution and absorption of respirable particles in the lung epithelium; XposeALI, a 3D cell exposure module that combines aerosol capability with 3D cell models cultured at an air liquid interface; Nose-only inhalation, a standard method of exposure used in preclinical testing of inhalation drugs, as well as for inhalation toxicity studies in rodents; and intratracheal exposure module, an unique technology delivering aerosol directly to the lungs, bypassing the nose, and to spontaneously breathing rodents. Inhalation Sciences Sweden AB (publ) was founded in 2004 and is headquartered in Huddinge, Sweden.
Inhalation Sciences Sweden AB (publ) Fundamentals Summary
| ISAB fundamental statistics | |
|---|---|
| Market cap | SEK 65.83m |
| Earnings (TTM) | -SEK 4.74m |
| Revenue (TTM) | SEK 17.50m |
3.8x
P/S Ratio-13.9x
P/E RatioIs ISAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ISAB income statement (TTM) | |
|---|---|
| Revenue | SEK 17.50m |
| Cost of Revenue | SEK 3.54m |
| Gross Profit | SEK 13.96m |
| Other Expenses | SEK 18.71m |
| Earnings | -SEK 4.74m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 28, 2024
| Earnings per share (EPS) | -0.31 |
| Gross Margin | 79.77% |
| Net Profit Margin | -27.10% |
| Debt/Equity Ratio | 8.4% |
How did ISAB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/04/29 11:20 |
| End of Day Share Price | 2024/01/31 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Inhalation Sciences Sweden AB (publ) is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gustaf Meyer | Redeye |